TickerTalks
Browse all tickers →
TickerTalks›$ERAS
ERERAS

Erasca, Inc.

$ERAS·$5.8B·Biotechnology·Healthcare
$19.13+0.6%YTD+412.7%1Y+1220.8%
Mentions · last 7 days
2026-07-10: 53 posts2026-07-11: 20 posts2026-07-12: 43 posts2026-07-13: 140 posts2026-07-14: 122 posts2026-07-15: 204 posts2026-07-16: 175 posts759+38%
Price updated 4m ago·X counts updated 18h ago
ERERAS
$ERASErasca, Inc.
$19.13+0.58%759 posts+38%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ERAS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-07-17

Catching its breath after a run — could pick back up or fade from here.

Cancer-biotech up 1,220% t12m just raised $517M into strength — trial data catalyst is what matters next.

Erasca is a clinical-stage precision-oncology biotech focused on RAS-mutant tumors — KRAS/NRAS/HRAS pathway mutations that account for a large share of colorectal, pancreatic, and lung cancers. Positive early data from ERAS-0015 drove the tape explosively higher.

Where the setup nets out:

  • Zero commercial revenue with severe burn: FY27 consensus revenue is $7.5M against a $5.8B market cap — the equity is entirely priced on future clinical outcomes.
  • The offering just landed and it was large: July 14 pricing of 31.4M shares at $17.50 (raised ~$517M gross) lets Erasca fund the ERAS-0015 pivotal program — but the dilution is meaningful.
  • Legal noise is escalating: multiple 'securities fraud class action' press releases through July are boilerplate follow-on to any biotech that both ran up and then diluted.
  • Position confirms the euphoria: YTD +413%, t12m +1,220%, and the $517M raise into strength is management's own tell they're comfortable diluting at these levels.
  • Merck M&A speculation exists (paired with RNGX in the community's mind) — worth acknowledging but not investable without more signal.

The forward view: the August 11 Q2 print handles cash runway; the real catalyst is the ERAS-0015 differential-efficacy data expected later this year (lung vs pancreatic cancer) — that either validates the run or gives it back. A Revolution Medicines competitive-data readout or a specific IP-overlap dispute with RVMD would break the cooling into a real reset.

Agrees with X sentimentThe mixed X read — bulls on the +500% ride, bears on RM-055 competitive risk and IP overlap with RVMD's daraxonrasib — is genuinely fair. Our take agrees the setup is coiled after the $517M raise and pivotal data is what decides direction.

What to watch: August 11 Q2 earnings for cash runway, and the ERAS-0015 differential-efficacy data readout later this year; a Revolution Medicines competitive-data readout or specific IP dispute would break the cooling into a real reset.

On the calendar: 2026-08-11 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment⚠10 posts analyzed · as of 2026-07-15 · top-engagement diverged

Erasca chatter is split. Bulls point to ERAS being +500% since one trader sold in December 2025. Long-term ERAS 30C 1/2028 saw ~600k of flow. ERAS could be a Merck ($MRK) acquisition target alongside RNGX. CEO stool-analogy commentary sets up a differential-efficacy data catalyst later this year for 0015 in lung vs pancreatic cancer. Bears warn RM-055 could make ERAS irrelevant and that the ERAS molecule development vs RVMD's daraxonrasib may have IP overlap. Buyout thesis mediocre with standalone-corp valuation only $5-7B. Genuinely two-sided.

Read the AI verdict + X sentiment for $ERAS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech targeting RAS/MAPK pathway cancers with small molecule inhibitor combinations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ERAS.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $ERAS

Direct beneficiary — Clinical-stage oncology biotech targeting RAS/MAPK pathway cancers with small molecule inhibitor combinations; the company is structurally positioned to capture the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-13.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-32.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-77.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 11, 2026$-0.60$-0.11-432.7%
Q4 2025Mar 12, 2026$-0.10$-0.11+9.1%
Q3 2025Nov 12, 2025$-0.11$-0.110.0%
Q2 2025Aug 12, 2025$-0.12$-0.120.0%
Next earningsTue, Aug 11·consensus EPS $-0.12

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.60$-27.4M
Q4 FY25$0———$-0.10$-21.7M
Q3 FY25$0———$-0.11$-21.7M
Q2 FY25$0———$-0.12$-20.6M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$7.5M$7.5M – $7.5M-$0.96-$1.01 – -$0.935
FY27$429K$429K – $429K-$0.56-$0.70 – -$0.504
FY28$3.7M$3.7M – $3.7M-$0.66-$0.91 – -$0.556
FY29$44.3M$44.3M – $44.3M-$0.78-$0.78 – -$0.785
FY30$281.8M$281.8M – $281.8M-$0.37-$0.37 – -$0.373

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.77%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+34.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+90.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 187.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today5.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.675-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellApr 1Ebun GarnerChief Legal Officer80.0K sh$1.3MSellMar 4Shannon MorrisChief Medical Officer20.0K sh$301K
+ 13 other (11 awards · 2 exempts) in window

See when $ERAS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Jul 14424B5
AI summary

Erasca (ERAS) — 424B5 final prospectus supplement for the sale of 31,428,572 shares at $17.50 per share, with a $1.05 per-share underwriting discount, generating approximately $517 million in gross proceeds. Shares settle and deliver on approximately July 15, 2026. Material — confirms the pricing and settlement of Erasca's ~$517M equity offering; dilutive for existing shareholders.

424B5Prospectus supplement (offering)Jul 13424B5
AI summary

Erasca (ERAS) — 424B5 prospectus supplement (July 13 filing version) for the sale of 31,428,572 shares at $17.50, with underwriters purchasing at $16.45. This is an earlier iteration of the same equity offering finalized on July 14. Material — confirms Erasca's dilutive ~$550M equity raise is proceeding under its automatic shelf registration.

S-3ASRAuto-shelf registrationJul 13S-3ASR
AI summary

Erasca (ERAS) — S-3ASR automatic shelf registration statement filed July 13, 2026. This shelf enables Erasca to offer and sell various securities from time to time on an expedited basis. The shelf was filed in connection with the contemporaneous ~$550M equity offering. Administrative — enabling shelf registration; the actual offering terms are in the concurrent 424B5 prospectus supplement.

8-KShareholder voteJul 18-K — Item 5.07: Shareholder vote
AI summary

Erasca held its 2026 Annual Meeting; specific vote details are not visible in the excerpt which cuts off at the cover page. Annual meeting voting results — administrative disclosure.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

ERAS filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-27. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

424B5Prospectus supplement (offering)Jan 22424B5
424B5Prospectus supplement (offering)Jan 20424B5
+ 20 other (6 routine 8-Ks · 6 13Gs · 3 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuitglobenewswire.com·1d agoROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERASnewsfilecorp.com·1d agoBronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harmnewsfilecorp.com·1d agoErasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERASglobenewswire.com·1d agoERAS DEADLINE: SueWallSt Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadlineprnewswire.com·1d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · top 7 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport